The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2026 | Deciding between bispecifics and CAR-T in R/R follicular lymphoma
Krish Patel, MD, Sarah Cannon Research Institute, Nashville, TN, discusses deciding between bispecific antibodies and CAR T-cell therapy for patients with relapsed/refractory follicular lymphoma (R/R FL). Dr Patel notes that CD19 CAR-T has shown impressive five-year follow-up data, while for patients who cannot access CAR-T, bispecific antibodies also offer a valuable option. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
